BioHarvest Sciences (NASDAQ:BHST) Announces Earnings Results

BioHarvest Sciences (NASDAQ:BHST) released its quarterly earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04), FiscalAI reports. The firm had revenue of $8.84 million for the quarter, compared to the consensus estimate of $9.45 million. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%.

BioHarvest Sciences Stock Performance

BHST stock traded up $0.01 during trading on Tuesday, reaching $2.11. 63,789 shares of the stock were exchanged, compared to its average volume of 36,372. BioHarvest Sciences has a twelve month low of $1.82 and a twelve month high of $12.80. The company has a market capitalization of $41.38 million, a P/E ratio of -3.57 and a beta of 0.98. The stock has a 50 day simple moving average of $2.77 and a 200-day simple moving average of $3.82. The company has a current ratio of 2.96, a quick ratio of 2.44 and a debt-to-equity ratio of 0.03.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, BioHarvest Sciences currently has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On BioHarvest Sciences

Several large investors have recently added to or reduced their stakes in BHST. Virtu Financial LLC bought a new stake in shares of BioHarvest Sciences in the 4th quarter worth approximately $60,000. Geode Capital Management LLC bought a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $61,000. HRT Financial LP bought a new stake in shares of BioHarvest Sciences during the fourth quarter valued at approximately $75,000. Marshall Wace LLP acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at $110,000. Finally, Quadrature Capital Ltd acquired a new position in shares of BioHarvest Sciences in the fourth quarter valued at $140,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.